StockLens

Lupin Limited (LUPIN) share price and analysis

LUPIN last traded at ₹1,950.00 (-1.35%) on the NSE. Market cap ₹89,172 Cr (Mid cap), Pharma & Healthcare sector.

Overall rating: 6.0/10 (Average)

Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.

Strengths of LUPIN

Weaknesses of LUPIN

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)17.2Cheaper than peers37.0–49.3 (sector median 41.1)
Forward P/E20.0Profits expected to fallbelow today's P/E (17.2) and near 41
Price / book3.71Low6–12 (high ROE allows more)
EPS (TTM)₹113.48Profitableabove ₹0
Return on equity23.9%Strong15%+ (below 10% is weak)
Debt / equity0.26Low debtbelow 1.0 (under 0.5 is great)
Net margin16.9%Healthy10%+ (below 5% is thin)
Operating margin23.4%Strong20%+ strong, below 10% thin
Revenue growth+11.1%Growing well10%+ a year (below 3% is weak)
Profit growth-22.1%Falling10%+ a year (falling is weak)
Dividend yield0.91%Small payout1.5%+ (none is fine for growth firms)
Current ratio1.84Comfortable1.5+ (below 1 is tight)
52W high₹2,529.5023% below · far from the highprice in the top 40% of its 52-week range
52W low₹1,892.90Price is 3% above it
50-DMA₹2,021.65Price 3.5% belowprice above it = short-term uptrend
200-DMA₹2,233.56Price 12.7% belowprice above it = long-term uptrend
1Y return-2.0%In line with Nifty 50Nifty 50 did −0.4%
Beta0.16Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider47.0%Moderate stake50%+ shows owner commitment
Institutions35.3%Strong big-investor interest30%+ is strong
Analyst target₹2,310.1118.5% upside · 36 analysts8%+ upside

Questions about LUPIN

What is the share price of Lupin Limited (LUPIN) today?

LUPIN last traded at ₹1,950.00 (-1.35% on the day) on the NSE. Its 52-week range is ₹1,892.90 to ₹2,529.50. Prices are delayed and come from Yahoo Finance.

Is LUPIN a good stock for the long term?

StockLens rates LUPIN 6.0 out of 10 (Average) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: cheap vs peers, high ROE, low debt. Concerns: downtrend, falling profits, bearish moving averages.

Is LUPIN share overvalued?

LUPIN trades at a P/E of 17.2 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 3.71.

Is LUPIN good for short-term trading?

The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 12.7% below its 200-day average and 14-day RSI is 40.

Which stocks are similar to LUPIN?

Similar Pharma & Healthcare stocks of comparable size include Max Healthcare, Aurobindo Pharma, Glenmark Pharmaceuticals, Cipla, Dr. Reddy's Laboratories. You can compare up to 4 of them side by side on StockLens.

About Lupin Limited

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Stocks similar to LUPIN

Compare LUPIN with MAXHEALTH, AUROPHARMA, GLENMARK

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.